



## **BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024**

March 6, 2024

**MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE)** -- [BioNTech SE](#) (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this [link](#). Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this [link](#).

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page in the Investor Relations section of the Company's website at <https://biontech.com/>. A replay of the webcast will be made available shortly after the call and archived on the Company's website for 30 days following the call.

### **About BioNTech**

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron and Pfizer.

For more information, please visit [www.BioNTech.com](http://www.BioNTech.com).

### **CONTACTS**

#### **Investor Relations**

Victoria Meissner, M.D.

+1 617 528 8293

[investors@biontech.de](mailto:investors@biontech.de)

#### **Media Relations**

Jasmina Alatovic

+49 (0)6131 9084 1513

[Media@biontech.de](mailto:Media@biontech.de)